The downward spiral in late-stage valuations finally subsided, according to the first cut of Carta’s Q2 data.
VCs backed away from Series A deals in Q1, but the seed market stayed resilient, signaling a divergence in how investors are approaching these stages.
Healthtech deal count declined in Q4, but deal value showed a slight uptick.
Received stock options from a startup and don't understand what that means or how they work? Here's how to make sense of your offer letter and option grant.
SaaS deal counts and dollars raised are down. Here's how SaaS investors see the landscape.